CLINICAL TRIALS PROFILE FOR FLONASE ALLERGY RELIEF

All Clinical Trials for Flonase Allergy Relief

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00119015 ↗	The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis	Terminated	Merck Sharp & Dohme Corp.	Phase 4	2005-07-01	Some people with nasal allergy symptoms continue to have symptoms even after treatment with a nasal steroid spray. The purpose of this study is to see if these patients are helped by adding another medication (montelukast) to their treatment compared to placebo (a substance that looks like the active medication but does not contain the drug).
NCT00119015 ↗	The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis	Terminated	University of Chicago	Phase 4	2005-07-01	Some people with nasal allergy symptoms continue to have symptoms even after treatment with a nasal steroid spray. The purpose of this study is to see if these patients are helped by adding another medication (montelukast) to their treatment compared to placebo (a substance that looks like the active medication but does not contain the drug).
NCT00275561 ↗	Topical Steroid Treatment for Eosinophilic Esophagitis	Completed	Mayo Clinic	Phase 2	2005-11-01	This was a randomized controlled trial of swallowed fluticasone vs. placebo for eosinophilic esophagitis. Eosinophilic esophagitis is an inflammatory condition in which the wall of the esophagus becomes filled with large numbers of eosinophils, a type of white blood cell. Patients who have this condition have difficulty in swallowing (dysphagia) solid food. Prior to treatment the patients had biopsies of their esophagus and took questionnaires regarding their symptoms. Treatment was given for 6 weeks, after which biopsies were taken from the esophagus to measure any changes in the tissue from before treatment. The primary endpoint was improvement in dysphagia as measured by the validated Mayo Dysphagia Questionaire. Secondary outcomes included partial symptom response, and histologic (tissue) response to treatment.
NCT00385463 ↗	Adolescent and Adult Subjects With Asthma and Seasonal Allergic Rhinitis Receiving Advair Diskus or Placebo	Withdrawn	GlaxoSmithKline	N/A	2006-04-01	The four respiratory drugs being researched in this study have been approved by the US Food and Drug Administration (FDA) and are currently available by prescription at your drug store. One of the drugs is for the treatment of asthma alone, one is for treatment of SAR alone, and one is for treatment of both SAR and asthma. In addition, you will also receive one asthma rescue drug (albuterol) that is to be used for any breakthrough asthma symptoms that you may experience throughout the study. The purpose of this study is to see how well your asthma and SAR are controlled when taking one of the medicine combinations
NCT00385463 ↗	Adolescent and Adult Subjects With Asthma and Seasonal Allergic Rhinitis Receiving Advair Diskus or Placebo	Withdrawn	Creighton University	N/A	2006-04-01	The four respiratory drugs being researched in this study have been approved by the US Food and Drug Administration (FDA) and are currently available by prescription at your drug store. One of the drugs is for the treatment of asthma alone, one is for treatment of SAR alone, and one is for treatment of both SAR and asthma. In addition, you will also receive one asthma rescue drug (albuterol) that is to be used for any breakthrough asthma symptoms that you may experience throughout the study. The purpose of this study is to see how well your asthma and SAR are controlled when taking one of the medicine combinations
NCT00550550 ↗	Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED)	Completed	ALK-Abelló A/S	Phase 3	2007-11-01	The purpose of the study is to investigate the efficacy and safety of a grass sublingual tablet in children and adolescents with a history of grass-pollen induced rhinoconjunctivitis with or without asthma.
NCT00550550 ↗	Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2007-11-01	The purpose of the study is to investigate the efficacy and safety of a grass sublingual tablet in children and adolescents with a history of grass-pollen induced rhinoconjunctivitis with or without asthma.

Clinical Trial Conditions for Flonase Allergy Relief

Condition Name

Condition Name for Flonase Allergy Relief
Intervention	Trials
Allergic Rhinitis	5
Seasonal Allergic Rhinitis	4
Rhinoconjunctivitis	2
Allergy	2

Condition MeSH

Condition MeSH for Flonase Allergy Relief
Intervention	Trials
Rhinitis	14
Rhinitis, Allergic	13
Rhinitis, Allergic, Seasonal	5
Conjunctivitis	4

Clinical Trial Locations for Flonase Allergy Relief

Trials by Country

Trials by Country for Flonase Allergy Relief
Location	Trials
United States	25
Ireland	1
Canada	1

Trials by US State

Trials by US State for Flonase Allergy Relief
Location	Trials
Massachusetts	3
California	3
New York	2
Missouri	2
Florida	2

Clinical Trial Progress for Flonase Allergy Relief

Clinical Trial Phase

Clinical Trial Phase for Flonase Allergy Relief
Clinical Trial Phase	Trials
Phase 4	9
Phase 3	7
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for Flonase Allergy Relief
Clinical Trial Phase	Trials
Completed	16
Terminated	3
Recruiting	2

Clinical Trial Sponsors for Flonase Allergy Relief

Sponsor Name

Sponsor Name for Flonase Allergy Relief
Sponsor	Trials
Merck Sharp & Dohme Corp.	7
Stanford University	2
ALK-Abelló A/S	2

Sponsor Type

Sponsor Type for Flonase Allergy Relief
Sponsor	Trials
Industry	16
Other	13
NIH	1